cisplatin + cyclophosphamide + etoposide

This is a combination chemotherapy regimen consisting of three cytotoxic agents—cisplatin, cyclophosphamide, and etoposide. Each drug has a distinct mechanism of action: - **Cisplatin** is a platinum-based compound that forms DNA crosslinks, leading to apoptosis by inhibiting DNA replication and transcription. - **Cyclophosphamide** is an alkylating agent that adds alkyl groups to DNA bases, resulting in DNA strand breakage and cell death. - **Etoposide** inhibits topoisomerase II, preventing the re-ligation of double-stranded breaks in DNA during replication. The combination is primarily used for the treatment of small-cell lung cancer (SCLC), particularly in extensive-stage or refractory cases. It has demonstrated high response rates but also significant hematologic toxicity. The regimen may be used as induction therapy or after failure of other chemotherapeutic regimens[1][2][8].

Brand names

PlatinolEtopophosCytoxanProcytox

Other names

cisplatin cyclophosphamide etoposide combinationCEP regimen